Second-line Drug Resistance Characterization in Mycobacterium tuberculosis by Genotype MTBDRsl Assay

Sunil Sethi; Priyanka Agarwal; Rajiv Khaneja; Naresh Kumar; Nitin Kumar; Jagesh Chandna; Ashutosh Nath Aggarwal; Rakesh Yadav

doi:10.2991/jegh.k.191215.003

<Previous Article In Issue

Next Article In Issue>

Volume 10, Issue 1, March 2020, Pages 42 - 45

Second-line Drug Resistance Characterization in Mycobacterium tuberculosis by Genotype MTBDRsl Assay

Authors

Sunil Sethi¹^{, *}^{, #}, Priyanka Agarwal²^{, #}, Rajiv Khaneja³, Naresh Kumar⁴, Nitin Kumar⁵, Jagesh Chandna⁵, Ashutosh Nath Aggarwal⁶, Rakesh Yadav¹

¹Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

²WHO Country Office for India, New Delhi, India

³State TB Cell, Sector 34, Chandigarh, India

⁴Directorate of Health Services, Sector 34, Chandigarh, India

⁵Intermediate Reference Lab, Patiala, Punjab, India

⁶Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India

^#

First two authors are joint first author.

^*Corresponding author. Email: sunilsethi10@hotmail.com

Corresponding Author

Sunil Sethi

Received 22 April 2019, Accepted 3 December 2019, Available Online 8 January 2020.

DOI: 10.2991/jegh.k.191215.003 How to use a DOI?
Keywords: Drug resistance; diagnosis; MTBDRsl Ver 2.0; Mycobacterium tuberculosis
Abstract: Tuberculosis (TB) remains a main hurdle for national programs due to increase in drug resistance to antitubercular drugs. World Health Organization (WHO)-endorsed Line Probe Assay, Genotype MTBDRsl Ver 2.0, gives opportunity for rapid diagnosis and molecular characterization of different mutations in drug targets of fluoroquinolone (FQ) and second-line injectable drugs (SLID). We, retrospectively, analyzed the data of Genotype MTBDRsl Ver 2.0 from January 2018 to June 2018. A total of 863 isolates of Mycobacterium tuberculosis, 687 rifampicin resistant and 176 isoniazid resistant only, were screened for drug resistance in FQ and SLID. All the isolates were tested for Genotype MTBDRsl Ver 2.0 according to the manufacturer’s instructions. The FQ and SLID resistance were detected in 295 (34.2%) and 70 (8.1%) isolates, respectively. Among newly diagnosed and follow-up rifampicin-resistant TB (RR TB) patients, the FQ resistance was 25.8% and 44.5%, respectively. The most common mutation (42.7%) in FQ-resistant isolates was MUT3C in gyrA gene. Both SLID and FQ resistance were detected in 59 (6.8%) RR TB isolates. The mono SLID resistance was detected in 12 (1.7%) isolates of RR TB. Genotype MTBDRsl Ver 2.0 assay is a rapid and important tool for the diagnosis and molecular characterization of second-line drug resistance under programmatic conditions.
Open Access: This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

<Previous Article In Issue

Next Article In Issue>

Journal: Journal of Epidemiology and Global Health
Volume-Issue: 10 - 1
Pages: 42 - 45
Publication Date: 2020/01/08
ISSN (Online): 2210-6014
ISSN (Print): 2210-6006
DOI: 10.2991/jegh.k.191215.003 How to use a DOI?
Open Access: This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Cite this article

ris enw bib

TY  - JOUR
AU  - Sunil Sethi
AU  - Priyanka Agarwal
AU  - Rajiv Khaneja
AU  - Naresh Kumar
AU  - Nitin Kumar
AU  - Jagesh Chandna
AU  - Ashutosh Nath Aggarwal
AU  - Rakesh Yadav
PY  - 2020
DA  - 2020/01/08
TI  - Second-line Drug Resistance Characterization in Mycobacterium tuberculosis by Genotype MTBDRsl Assay
JO  - Journal of Epidemiology and Global Health
SP  - 42
EP  - 45
VL  - 10
IS  - 1
SN  - 2210-6014
UR  - https://doi.org/10.2991/jegh.k.191215.003
DO  - 10.2991/jegh.k.191215.003
ID  - Sethi2020
ER  -

download .riscopy to clipboard